ClinicalTrials.gg
CompletedNCT00651313Lidocaine 04Updated Feb 17, 2012Results posted

Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)

A Phase 2 interventional study of Lidocaine and Placebo in Dysmenorrhea, sponsored by Juniper Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Juniper Pharmaceuticals, Inc. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Dysmenorrhea with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Dysmenorrhea · United States.

Enrollment
30th of 62
81 · median 73
Started
2007
with 1 other
Phase 2
12 of 68
none open now
Registered
9th of 68
by date

Among the 68 studies in Dysmenorrhea with a site in United States, this one is the 30th largest by enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2007, is one of 12 in phase 2, and was the 9th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

9 of the 68 studies in Dysmenorrhea with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Dysmenorrhea with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether lidocaine vaginal gel is safe and effective for preventing or reducing the severity of dysmenorrhea (painful menstrual periods) compared to placebo (inactive gel).

Read the detailed description

The primary objective of this study is to evaluate the efficacy of 10% (150 mg) lidocaine gel compared with placebo in reducing the severity and onset of primary dysmenorrhea in women with recurrent dysmenorrhea.

The secondary objectives of this study are the following:

  • to assess the safety of 10% (150 mg) lidocaine gel compared with placebo
  • to evaluate electrocardiograms (ECGs) for potentially significant QT changes at approximate peak lidocaine plasma concentration after 4 days of dosing with 10% (150 mg) lidocaine gel.
03

Conditions studied

  • Dysmenorrhea

Browse trials for

Keywords

  • Dysmenorrhea
  • Periods
  • Menstrual
  • Primary dysmenorrhea in women with recurrent dysmenorrhea
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Experiences primary dysmenorrhea requiring pain medication for moderate-to-severe pain (as measured by a 4-point categorical rating scale) by the subject's own report for at least four of the previous six menstrual cycles.
  2. Has a history of primary dysmenorrhea with onset within 4 years of menarche.
  3. Has regular menstrual cycles (i.e. onset of menses predictable within 1 - 2 days each month) for the 3 month period preceding enrollment. If a subject has had regular cycles for the past 12 months but had a single cycle that was not regular within the 3 month period preceding enrollment, the subject may be enrolled at investigator discretion after consultation with sponsor.
  4. Taking the same strength and type of hormonal on a monthly cycle for at least the previous 6 months prior to screening and plans to remain on this hormonal contraception for the duration of participation in the study or is on an acceptable method of birth control including surgical sterilization (i.e. bilateral tubal ligation, partner vasectomy), double-barrier methods, and total abstinence (at the discretion of the investigator in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance).
  5. Is a tampon user and/or must be willing to use tampons throughout the study dosing period.
  6. Age 18 to 40 years (inclusive).
  7. Has a (BMI) ≤ 35 kg/m2.
  8. Able to understand and willing to complete the efficacy evaluations.
  9. Able to speak and understand English, and must give written for the study.

Exclusion criteria

Exclusion Criteria:

  1. Unable, in the opinion of the Investigator, to comply fully with any of the study requirements.
  2. Experiencing pelvic pain other than that thought to be associated with primary dysmenorrhea, such as chronic pelvic pain occurring at times other than exclusively during menses and/or dyspareunia.
  3. Experiencing dysmenorrhea symptoms that are effects of or thought to be effects of (at least in part) secondary causes of dysmenorrhea, such as uterine fibroids, endometriosis, and/or currently symptomatic ovarian cysts.
  4. Experienced dysmenorrhea that did not require, in the opinion of the subject, the use of analgesic medication during four of the previous six menstrual episodes.
  5. Has dysmenorrhea to treatment with commonly used analgesic medications for the treatment of menstrual pain (e.g., ibuprofen or naproxen sodium).
  6. Use of any Class I antiarrhythmic drug.
  7. Currently using injection, implant, or extended cycle OC (hormonal contraceptive cycles consisting of 28 days or more of active hormones).
  8. Pregnant or breastfeeding.
  9. Participated in a clinical trial in the 30 days from the time of last dosing in the prior study to the time of providing consent for this study.
  10. Previously randomized into this study.
  11. A history of allergic or significant intolerance (including angioedema, urticaria, bronchospasm, and rhinitis) related to treatment with any medications used in this study.
  12. A history of past or ongoing disease, illness, or disorder that, in the opinion of the Investigator, makes the subject unsuitable for study participation including active vaginal, vulvar, and cervical lesions.
  13. Laboratory abnormalities that, in the opinion of the Investigator, could contraindicate study participation such as liver function tests > 1.5 times the (At the Investigator's discretion, laboratory tests may be repeated once for verification.)
  14. A history of, within the past 4 years, or ongoing significant psychiatric illness that, in the opinion of the Investigator, makes the subject unsuitable for study participation.
  15. A history of chronic analgesic or tranquilizer use or drug abuse including alcohol within the 6 months before providing consent for this study.
  16. Regular use of any concomitant medications that might confound efficacy and/or safety assessments, in the opinion of the Investigator, including, but not limited to, the following: psychotropic drugs, antidepressants, sedative-hypnotics, sedating antihistamines, or tranquilizers for 24 hours or five half-lives prior to providing until 24 hours after the final treatment cycle. Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and St. John's Wort are permitted for indications other than pain if the subject has been on a stable dose for at least 2 weeks before providing consent for this study and agrees to remain on a stable dose throughout the course of the study.
  17. Unwilling to use only those medications that are allowed in the study for the treatment of their dysmenorrhea, i.e., study drug and rescue medication.
  18. Any ongoing vaginal infection requiring intravaginal treatment.
  19. A history of toxic shock syndrome (TSS).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    Active

    Lidocaine 10% (150mg) vaginal gel

    Drug: Lidocaine

  • Placebo comparator
    Placebo

    Placebo vaginal gel

    Drug: Placebo

Interventions

  • Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days

  • DrugPlacebo

    Placebo vaginal gel administered once daily for 4 days

06

What researchers measure

Primary outcomes

  1. The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale.

    Time frame: Two 4-day dosing regimens for two consecutive monthy menstrual cycles

  2. Treatment-emgergent Adverse Events

    Time frame: approximately two months, based on onset of menses

Secondary outcomes

  1. Evaluate Electrocardiograms (ECGs) for Potentially Significant QT Changes at Approximate Peak Lidocaine Plasma Concentration After 4 Days of Dosing

    Time frame: 7 hours following fourth dose in 2 consecutive menstrual cycles

07

Results

Posted Jul 6, 2011

Participant flow

Clinics and private practice offices; 8/31/07-6/13/08. Maximum patient participation was approx 4 months, including 45 day screening period, a treatment period of approx 8 weeks duration (during which subjects received study drug on a total of 8 days), and a post treatment visit occurring 2 - 3 weeks after Treatment Cycle 2,Visit 5.

Participant flow — Overall Study
MilestoneActivePlacebo
Started4143
Completed3537
Not completed66
Withdrew: Adverse event01
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up11
Withdrew: Adminstrative discontinuation23

Outcome measures

PrimaryThe Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale.
Time frame:
Two 4-day dosing regimens for two consecutive monthy menstrual cycles
Reported as:
Mean · units on a scale
The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale.
units on a scaleLidocaine 10%Placebo Gel
The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale.0.91 ± 0.6350.92 ± 0.552
PrimaryTreatment-emgergent Adverse Events
Time frame:
approximately two months, based on onset of menses

Results for this outcome have not been posted.

SecondaryEvaluate Electrocardiograms (ECGs) for Potentially Significant QT Changes at Approximate Peak Lidocaine Plasma Concentration After 4 Days of Dosing
Time frame:
7 hours following fourth dose in 2 consecutive menstrual cycles

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active—0/77 (0%)6/77 (7.8%)
Placebo—0/77 (0%)7/77 (9.1%)
Most frequent other events
Most frequent other events
EventActivePlacebo
HeadacheNervous system disorders6/777/77

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ActivePlaceboTotal
<=18 years000
Between 18 and 65 years414384
>=65 years000
Age Continuous
Age Continuous(years)ActivePlaceboTotal
Mean26.5 ± 7.2027.7 ± 6.6927.1 ± 6.92
Sex: Female, Male
Sex: Female, Male(Participants)ActivePlaceboTotal
Female414384
Male000
Region of Enrollment
Region of Enrollment(participants)ActivePlaceboTotal
United States414384
08

Study locations

4 sites
  • Lyndhurst Gynecologic Associates
    Winston-Salem, North Carolina 27103, United States
  • SCIREX Research Center
    Memphis, Tennessee 38120, United States
  • SCIREX Research Center
    Austin, Texas 78705, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jun 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2008
First posted
Apr 2, 2008
Start
Aug 2007
Primary completionActual
Jun 2008
CompletionActual
Aug 2008
Results first posted
Jul 6, 2011
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00651313
Lead sponsor
Juniper Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2008
Start date
Aug 2007
Primary completion
Jun 2008
Completion
Aug 2008
Results posted
Jul 6, 2011
Last update
Feb 17, 2012

Study contacts

George W Creasy, MD
study director · Juniper Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion